This global pharmaceutical company is dedicated to improving patients' lives through high-quality, differentiated products and services. They leverage a collaborative network to achieve success in key regions like the EU and North America. Their focus areas include women's health, infectious diseases, and potentially other therapeutic areas based on their recent approvals and launches. They produce prescription medications (including injectables) and tablets, demonstrating expertise in various dosage forms. The company holds GMP certifications and boasts successful product patents, solidifying its commitment to quality and innovation.

Established in 1993, this manufacturer employs over 1,100 staff and operates advanced production lines for metered dose inhalers, nasal sprays, dry powder inhalers, and nebulizer solutions. As a CTD dossier owner and manufacturer, it holds GMP approvals from more than 20 countries, including Australia. The manufacturer is recognized as a CTD dossier owner and manufacturer, and its products are distributed in over 90 countries worldwide. With a focus on innovation, the manufacturer is a CTD dossier owner and manufacturer, dedicated to developing high-end generic drugs